Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fezolinetant for Vasomotor Symptoms in Men Receiving ADT for Prostate Cancer
NCT07568236Phase 2Recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fezolinetant in vasomotor symptoms, sponsored by The Chinese University of Hong Kong. Started Oct 2026; status: recruiting.
02
Drugs
fezolinetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT07568236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07568236.